300841 康华生物
2024/03 - 三个月2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)4.20115.45520.81735.71732.015
总资产报酬率 ROA (%)3.55412.85817.77632.11528.768
投入资产回报率 ROIC (%)3.96814.66520.24735.62231.836

边际利润分析
销售毛利率 (%)95.84793.52493.56293.52093.949
营业利润率 (%)55.29036.55547.38370.85546.702
息税前利润/营业总收入 (%)54.57935.88546.50769.20545.424
净利润/营业总收入 (%)48.00332.28241.33964.17939.287

收益指标分析
经营活动净收益/利润总额(%)102.537107.69097.33970.49198.774
价值变动净收益/利润总额(%)0.356-5.4448.32229.9240.459
营业外收支净额/利润总额(%)-0.006-0.456-0.250-0.020-0.232

偿债能力分析
流动比率 (X)4.4933.8973.5075.73110.448
速动比率 (X)4.1723.6433.2565.42010.155
资产负债率 (%)14.29516.51617.12211.5220.081
带息债务/全部投入资本 (%)5.3495.0864.4730.0220.000
股东权益/带息债务 (%)1,763.6891,859.1922,130.120449,460.361--
股东权益/负债合计 (%)599.534505.461484.054767.9001,139.684
利息保障倍数 (X)-77.082-71.230-61.344-42.318-38.835

营运能力分析
应收账款周转天数 (天)400.644307.828264.297165.712109.038
存货周转天数 (天)1,261.886576.539500.834334.013282.245